New kidney drug passes early safety check in small study
NCT ID NCT02837237
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 15 times
Summary
This early-stage study tested a single dose of the experimental drug KBP-5074 in 11 people with severe chronic kidney disease, including some on dialysis. The main goal was to check safety and how the drug moves through the body. No treatment benefits were measured; the study was designed to gather information for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
KBP Biosciences USA Inc
Princeton, New Jersey, 08540, United States
Conditions
Explore the condition pages connected to this study.